Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: Relevance for biomarker development

Multiple Sclerosis Journal

Volumn 20, Issue 4, 2014, Pages 438-444

  Kivisäkk, Pia ^a   Healy, Brian C ^a,b   Francois, Katiana ^a   Gandhi, Roopali ^a   Gholipour, Taha ^a   Egorova, Svetlana ^a   Sevdalinova, Velina ^a   Quintana, Francisco ^a   Chitnis, Tanuja ^a   Weiner, Howard L ^a   Khoury, Samia J ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Biomarker; disease; ELISA; multiple sclerosis; osteopontin; plasma

Indexed keywords

BIOLOGICAL MARKER; GLATIRAMER; NATALIZUMAB; OSTEOPONTIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; DISEASE CLASSIFICATION; FOLLOW UP;

BIOMARKER; DISEASE; ELISA; MULTIPLE SCLEROSIS; OSTEOPONTIN; PLASMA;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BRAIN; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OSTEOPONTIN; PEPTIDES;

EID: 84896123714     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513503052     Document Type: Article

References (33)

1. Martin R, Bielekova B, Hohlfeld R, et al. Biomarkers in multiple sclerosis. Dis Markers. 2006 ; 22: 183-185
2. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: Potential for use in therapeutic decision making. Molec Diag Ther. 2009 ; 13: 225-244
3. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Nat Can Inst. 2008 ; 100: 1432-1438
4. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nature Rev Immunol. 2009 ; 9: 440-447
5. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001 ; 294: 1731-1735
6. Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol. 2005 ; 158: 231-239
7. Börnsen L, Khademi M, Olsson T, et al. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler. 2011 ; 17: 32-42
8. Vogt MH, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol. 2003 ; 53: 819-822
9. Vogt MH, Ten Kate J, Drent RJ, et al. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler. 2010 ; 16: 443-449
10. Vogt MH, Floris S, Killestein J, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol. 2004 ; 155: 155-160
11. Gauthier SA, Glanz BI, Mandel M, et al. A model for the comprehensive investigation of a chronic autoimmune disease: The multiple sclerosis CLIMB study. Autoimmunity Rev. 2006 ; 5: 532-536
12. Gauthier SA, Glanz BI, Mandel M, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurological Sci. 2009 ; 284: 116-119
13. Khademi M, Stol D, Olsson T, et al. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. Eur J Neurol. 2008 ; 15: 309-312
14. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006 ; 59: 748-754
15. Kivisäkk P, Healy BC, Viglietta V, et al. Natalizumab treatment in MS is associated with sequestration of proinflammatory T cells in peripheral blood. Neurology. 2009 ; 72: 1922-1930
16. Börnsen L, Christensen JR, Ratzer R, et al. Effect of natalizumab on circulating CD4+ T cells in multiple sclerosis. PLoS ONE. 2012 ; 7: e47578
17. De Andres C, Teijeiro R, Alonso B, et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS ONE. 2012 ; 7: e34103
18. Begum-Haque S, Christy M, Wang Y, et al. Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17 and RORgammat responses and by increasing IL-10 production in experimental allergic encephalomyelitis. J Neuroimmunol. 2013 ; 254: 117-124
19. Rodrigues LR, Teixeira JA, Schmitt FL, et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomark Prevent. 2007 ; 16: 1087-1097
20. Sodek J, Batista Da, Silva AP, Zohar R. Osteopontin and mucosal protection. J Dental Res. 2006 ; 85: 404-415
21. Braitch M, Nunan R, Niepel G, et al. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol. 2008 ; 65: 633-635
22. Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol. 2008 ; 65: 232-235
23. Brown LF, Papadopoulos-Sergiou A, Berse B, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol. 1994 ; 145: 610-623
24. Senger DR, Perruzzi CA, Gracey CF, et al. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988 ; 48: 5770-5774
25. Sennels H, Sorensen S, Ostergaard M, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol. 2008 ; 37: 241-247
26. Masi L, Ricci L, Zulian F, et al. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. J Rheumatol. 2009 ; 36: 2308-2313
27. Samitas K, Zervas E, Vittorakis S, et al. Osteopontin expression and relation to disease severity in human asthma. Eur Resp J. 2011 ; 37: 331-341
28. Chen YJ, Shen JL, Wu CY, et al. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol. 2009 ; 60: 225-230
29. Stepien E, Wypasek E, Stopyra K, et al. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem. 2011 ; 44: 826-831
30. Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003 ; 170: 333-337
31. Waller AH, Sanchez-Ross M, Kaluski E, et al. Osteopontin in cardiovascular disease: A potential therapeutic target. Cardiol Rev. 2010 ; 18: 125-131
32. Bishop E, Theophilus EH, Fearon IM. In vitro and clinical studies examining the expression of osteopontin in cigarette smoke-exposed endothelial cells and cigarette smokers. BMC Cardiovasc Disord. 2012 ; 12: 75
33. Szalardy L, Zadori D, Simu M, et al. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. J Neurolog Sci. 2013 ; 331: 38-42